市場調查報告書
商品編碼
1368679
適體市場規模 - 按類型(DNA、RNA 適體)、應用(研究與開發、診斷)、技術 (SELEX)、最終用途和全球預測 - 2023 年 - 2032 年Aptamers Market Size - By Type (DNA, RNA-Based Aptamers), Application (Research & Development, Diagnostics), Technology (SELEX), End-use & Global Forecast - 2023 - 2032 |
由於慢性病盛行率上升以及對標靶治療和個人化醫療解決方案的需求激增,預計 2023 年至 2032 年適體市場規模將以超過 20% 的年複合成長率成長。適體因其對各種疾病標靶的高特異性和親和力,作為傳統治療方式的可行替代方案而受到關注。由於其具有精確有效的藥物輸送潛力以及最小的脫靶效應和降低的免疫原性,適配體正在滿足對個人化醫療解決方案不斷成長的需求。
此外,產業參與者正在投資研發活動,以推動適配體技術的進步。例如,2023 年 10 月,Zentek Ltd. 與麥克馬斯特大學合作成立了一家全資子公司,該子公司將擁有所有基於適配體的技術的獨家國際許可權。
整個適配體市場分為類型、應用、技術、最終用途和區域。
根據類型,基於 RNA 的適配體產業預計將在 2023 年至 2032 年期間獲得顯著成長。憑藉其與多種標靶分子結合的獨特能力,基於RNA的適配體在治療、診斷和研究應用領域引起了極大的關注。此外,RNA適體選擇技術的不斷進步,包括改進的SELEX方法和正在進行的研發活動,以探索基於RND的適體的潛在應用,將推動該細分市場的成長。例如,2023 年 9 月,FDA 授權 Iveric Bio/Astellas 的 avacincapad pegol 治療繼發性地圖樣萎縮,以治療老年黃斑部病變。
在應用方面,預計到2032 年,診斷領域的適配體市場規模將實現強勁成長。由於其快速、靈敏的檢測能力以及更高的多重檢測潛力和經濟高效的生產,適配體已成為診斷領域的寶貴工具。診斷分析的發展。隨著各種醫療保健環境和進步對準確、高效的診斷解決方案的需求激增,該領域有望實現可觀的成長。
從地區來看,亞太地區適配體產業在 2022 年錄得強勁收益,預計由於對生物技術研發活動的日益關注,特別是在中國、日本和印度,該產業將顯著成長。慢性病盛行率不斷上升,加上人口眾多和老化,刺激了該地區對有效和有針對性的治療解決方案的需求,進一步推動了適體的採用。此外,政府促進生物製藥產業發展的舉措,加上學術研究機構和產業參與者之間不斷加強的合作,將推動市場成長。
Aptamers Market size is estimated to grow at more than 20% CAGR from 2023 to 2032, driven by the rising prevalence of chronic diseases coupled with the surging need for targeted therapies and personalized medicine solutions. Aptamers, with their high specificity and affinity for various disease targets, are gaining traction as viable alternatives to conventional treatment modalities. Owing to their potential for precise and efficient drug delivery along with minimal off-target effects and reduced immunogenicity, aptamers are matching the growing demand for personalized medicine solutions.
Moreover, industry players are investing in R&D activities for the advancement of aptamer technology. For instance, in October 2023, Zentek Ltd. partnered with McMaster University to launch a fully owned subsidiary that would own the exclusive, international licensing rights for all aptamer-based technology.
The overall aptamers market is segmented into type, application, technology, end-use, and region.
Based on type, the RNA-based aptamers industry is set to gain significant traction from 2023-2032. With their unique ability to bind to wide range of target molecules, RNA-based aptamers have garnered significant attention in the field of therapeutics, diagnostics, and research applications. Moreover, the rising advancements in RNA aptamer selection techniques, including modified SELEX methodologies and the ongoing R&D activities to explore the potential applications of RND-based aptamers will propel the segment growth. For instance, in September 2023, the FDA authorized Iveric Bio/Astellas' avacincaptad pegol for geographic atrophy secondary to treat age-associated macular degeneration.
In terms of application, the aptamers market size from the diagnostics segment is expected to record robust growth through 2032. Owing to their rapid and sensitive detection capabilities along with higher potential for multiplexing and cost-effective production, aptamers have emerged as valuable tools in the development of diagnostic assays. With the upsurge in demand for accurate and efficient diagnostic solutions across various healthcare settings and advancements, the segment is poised to record considerable growth.
Regionally, the Asia Pacific aptamers industry recorded robust proceeds in 2022 and is expected to foresee significant growth fueled by the increasing focus on biotechnological R&D activities, particularly in China, Japan, and India. The rising prevalence of chronic diseases coupled with the presence of large and aging population is bolstering the demand for effective and targeted therapeutic solutions in the region, further driving the adoption of aptamers. Additionally, government initiatives for promoting the development of the biopharmaceutical sector coupled with increasing collaboration between academic research institutions and industry players will propel the market growth.